ArticleCurrent microbiology2025
Proteomic Analysis of Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Under Aminoglycoside Drug Pressure.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacoproteomics enables the actual status of the drug-induced conditions at the protein level. Aminoglycosides have been a major component of second-line anti-TB therapy and with a well-known mechanism to inhibit protein synthesis in bacteria by interacting with several steps of the translational process. Researchers suggested the benefit of treating antibiotic-resistant M. tuberculosis strains with the same antibiotics at an effective and safe level. In this study, we analyzed the pharmaco-proteomic effects of aminoglycosides on eight drug-resistant clinical isolates by 2DE coupled with MALDI-TOF MS. Further, bioinformatics tools have been employed to characterize the protein-antibiotic interactions. This study revealed that nine proteins showed consistently increased intensities under drug pressure. 60 kDa chaperonin1 (Rv3417c) is a heat shock protein (Hsp) that plays a key role in the survival of bacilli under stress conditions. Elongation factor Tu (Rv0685) promotes GTP-dependent binding of aminoacyl-tRNA to the A-site of the ribosome during protein biosynthesis. Dihydrolipoyl dehydrogenase (Rv0462) is involved in energy metabolism. Ribosome recycling factor Rv2882c is responsible for increasing the efficiency of translation by recycling ribosomes from one round of translation to another. Proteasome subunit beta (Rv2110c) is involved in protein degradation. Antigen 85-A precursor (Rv3804c) is involved in cell-wall mycoloylation. Three proteins (Rv2623, Rv3389c, and Rv2744c) were identified with unknown functions. Overexpressed proteins and pathways could be directly/indirectly involved in aminoglycoside resistance. Bioinformatics revealed that three proteins of unknown functions showed good binding with aminoglycosides, suggesting their direct/indirect role in resistance, and need further exploration.
Indexed as
Identifiers
40608075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.